Prognostic effect of MRD on CIR, NRM, and OS if measured in peripheral blood (PB) or in bone marrow (BM). (A) CIR and NRM by competing risk analysis for MRD⁺ positive (n = 24) and MRD⁻ patients (n = 32) in whom MRD was quantified in PB. (B) CIR and NRM by competing risk analysis for MRD⁺ (n = 19) and MRD⁻ patients (n = 21) in whom MRD was quantified in BM. (C) OS for MRD⁺ (n = 24) and MRD⁻ patients (n = 32) in whom MRD was quantified in PB. (D) OS for MRD⁺ (n = 19) and MRD⁻ patients (n = 21) in whom MRD was quantified in BM.